Literature DB >> 26962747

Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia.

.   

Abstract

Entities:  

Year:  2016        PMID： 26962747     DOI： 10.1056/NEJMx160005

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  14 in total

Review 1.  Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.

Authors:  Sayed Shahabuddin Hoseini; Nai-Kong V Cheung
Journal:  Cancer Lett       Date:  2017-04-17       Impact factor: 8.679

2.  Reforming the Chimeric Antigen Receptor by Peptide Towards Optimized CAR T Cells With Enhanced Anti-Cancer Potency and Safety.

Authors:  Cuijuan Liu; Lin Li; Fan Gao; Jundong Zhou; Yingzhou Qin; Xin Yuan; Guang Yang; Yimin Zhu
Journal:  Front Bioeng Biotechnol       Date:  2022-06-17

Review 3.  Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors.

Authors:  Eric D Brooks; Jonathan E Schoenhals; Chad Tang; Goran Micevic; Daniel R Gomez; Joe Y Chang; James W Welsh
Journal:  Cancer J       Date:  2016 Jul-Aug       Impact factor: 3.360

4.  The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer.

Authors:  Wei Zhao; Lizhou Jia; Mingjiong Zhang; Xiaochen Huang; Peng Qian; Qi Tang; Jin Zhu; Zhenqing Feng
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

5.  Neurological complications of new chemotherapy agents.

Authors:  Alicia M Zukas; David Schiff
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

6.  Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.

Authors:  Jiayi Yu; Xiaowen Wu; Junya Yan; Huan Yu; Longwen Xu; Zhihong Chi; Xinan Sheng; Lu Si; Chuanliang Cui; Jie Dai; Meng Ma; Tianxiao Xu; Yan Kong; Jun Guo
Journal:  J Hematol Oncol       Date:  2018-01-03       Impact factor: 17.388

Review 7.  Genetically engineered T cells for cancer immunotherapy.

Authors:  Dan Li; Xue Li; Wei-Lin Zhou; Yong Huang; Xiao Liang; Lin Jiang; Xiao Yang; Jie Sun; Zonghai Li; Wei-Dong Han; Wei Wang
Journal:  Signal Transduct Target Ther       Date:  2019-09-20

8.  A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.

Authors:  Ying Zhang; Jiaqi Li; Xiaoyan Lou; Xiaochen Chen; Zhou Yu; Liqing Kang; Jia Chen; Jin Zhou; Xiangping Zong; Zhen Yang; Minghao Li; Nan Xu; Sixun Jia; Hongzhi Geng; Guanghua Chen; Haiping Dai; Xiaowen Tang; Lei Yu; Depei Wu; Caixia Li
Journal:  Front Oncol       Date:  2021-05-25       Impact factor: 6.244

Review 9.  CAR-T cells: Early successes in blood cancer and challenges in solid tumors.

Authors:  Hassan Dana; Ghanbar Mahmoodi Chalbatani; Seyed Amir Jalali; Hamid Reza Mirzaei; Stephan A Grupp; Eloah Rabello Suarez; Catarina Rapôso; Thomas J Webster
Journal:  Acta Pharm Sin B       Date:  2020-11-02       Impact factor: 11.413

10.  Lack of tocilizumab effect on mortality in COVID19 patients.

Authors:  Gregory E Holt; Mayank Batra; Mukunthan Murthi; Shweta Kambali; Kayo Santos; Maria Virginia Perez Bastidas; Huda Asif; Sara Haddadi; Sixto Arias; Mehdi Mirsaeidi
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.